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Abstract
Background: The -1438A/G polymorphism of the 5-HT2A gene has been found to be associated with
clinical response to clozapine and other second generation antipsychotics. Testing the impact of this
marker on response to first generation antipsychotics (which have a lower affinity for the 5-HT2A
receptor) provides the opportunity to help disentangling the two different roles that this polymorphism
might have. A psychopharmacogenetic role should be detected only for antipsychotics with high affinity to
the 5-HT2A receptor (therefore to second generation antipsychotics). An alternative role would imply
tagging a subgroup of patients responsive to any antipsychotic, whatever their affinity, meaning that the
association is more depending on non pharmacological charaterictics, such as clinical specificities.
Methods: A family-based sample of 100 Algerian patients with schizophrenia (according to DSM-IV
criteria) and their 200 biological parents was recruited, in order to avoid stratification biases. Patients were
all treated, or have been treated, by conventional antipsychotics (mainly haloperidol) for at least four
weeks, at appropriate dosage. May and Dencker scale was used to distinguish responders and non
responders.
Results: No allele of the -1438A/G polymorphism of the 5-HT2A gene was transmitted in excess (50
transmitted for 38 untransmitted) in the whole sample of patients with schizophrenia (p = .90). In contrast,
a significant excess of transmission of the G allele was observed (p = .02) in the subgroup of patients with
good treatment response (17 transmitted for 6 untransmitted).
Conclusion: Using a TDT approach, we showed that the G allele of the -1438A/G polymorphism of the
gene coding for the 5-HT2A receptor was associated to schizophrenia with good response to conventional
antipsychotics, although this conclusion is based on 88 informative patients only. Because previous data
showed the same result with atypical antipsychotics, it can be concluded that the G allele tags a subgroup
of schizophrenic patients with greater chance of improvement with antipsychotics of either type.
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There are large inter-individual differences in the clinical
efficacy of antipsychotics in schizophrenia. Age at onset of
schizophrenia, severity of the disorder, presence of extra-
pyramidal symptoms and tardive dyskinesia may be
involved in such variability [1-4]. Psychopharmacogenet-
ics may give valuable clues to potentially help the clini-
cian to prescribe the most appropriate treatment for each
patient, notably by allowing an estimate of individual risk
of antipsychotic refractoriness or severe side effects [5].
Based on the pharmacological profile of second genera-
tion antipsychotics, one of the most frequently studied
genes in this domain has been the gene coding for the 5-
HT2A receptor. Indeed, as compared to conventional
antipsychotics, second generation (or atypical) antipsy-
chotic drugs have higher affinity for this receptor than for
the dopamine D2 receptors [6]. The 5-HT2A gene is located
at chromosome region 13q14.2 in a locus that has been
linked with schizophrenia [7], but with conflicting results
regarding association studies [8]. Two common single
nucleotide polymorphisms (in almost complete linkage
disequilibrium) of this gene have already been tested in
schizophrenia, a silent variation in exon 1 (T102C) and
an upstream polymorphism in the promoter (-1438A/G).
Both T102C and -1438A/G SNPs may affect 5-HT2A recep-
tor expression, in a tissue-specific manner [9].
The T102C polymorphism of the 5-HT2A gene has been
associated with good clinical response to clozapine in one
study [10], but not in five others [11-16]. According to
Arranz et al. [17,18], the second polymorphism (-1438A/
G) would also be associated with the quality of response
to clozapine. These authors reported that 373 patients
(extracted from six different studies), that responded well
to clozapine had a moderate but significant excess of AA
genotype (OR = 1.36) compared to 360 non-responders
[18]. In contrast, a later study on a large Asian population
of schizophrenic patients, treated with risperidone,
another second generation antipsychotic, showed a better
outcome for patients with the GG genotype [19]. The
exact role of the 5-HT2A gene in the response to treatment
with second generation antipsychotics is therefore diffi-
cult to assess on the basis of such heterogeneous data.
Case control studies are exposed to population stratifica-
tion bias, i.e. allele variability may be explained by differ-
ences in ethnic background of the compared populations,
rather than the quality of a trait such as treatment
response. Although more difficult to perform, family
based association studies offer an interesting approach, as
they are protected from such bias. However, to date, such
studies have only been rarely undertaken for psychophar-
macogenetic purpose.
On the other hand the exact role of a candidate gene in a
complex disorder is always difficult to determine. For
example, we showed that both positive and negative
symptoms of schizophrenia have to be taken into account
when assessing the possible role of the 5-HT2A gene in
treatment response. In our sample, the -1438 A allele of
the 5-HT2A gene was found to be associated with the sever-
ity of negative symptoms, which by itself was sufficient to
predict refractoriness [20]. Accordingly, careful considera-
tion to the clinical specificities of the sample may help dis-
entangling the exact role of a candidate gene regarding
vulnerability/resistance to a disease or its response to
treatment.
In this context, it is surprising that the role of the 5-HT2A
gene in the response to first generation antipsychotics has
so rarely been investigated. Indeed, if the -1438 A allele is
tagging a subgroup of patients with lower chance of treat-
ment response [19], then it is expected that this allele
would have a similar role in case of treatment with all
antipsychotics, independently of their high or low affinity
for the 5-HT2A receptor. In contrast, if the -1438 A allele is
more directly involved in the mechanism of action of sec-
ond generation antipsychotics, then we should observe no
role of this gene in the response to first generation antip-
sychotics with low affinity for the 5-HT2A receptor.
In the present family-based association study, we directly
addressed this question by quantifying -1438A/G poly-
morphism in a sample of schizophrenic patients treated
with conventional antipsychotics (mainly haloperidol)
and their parents. We used a Transmission Disequilibrium
Test (TDT) considering the observed transmission of the
marker from heterozygous parents to the affected off-
spring compared to expected transmission (50%). This
approach increases the power to uncover a linkage [21].
Our hypothesis was that the -1438A/G polymorphism
was associated with treatment response also in patients
treated with first generation antipsychotics.
Methods
Clinical sample
The sample consisted of 101 Algerian patients with schiz-
ophrenia and their 202 biological parents. All subjects
were of Algerian origin and had a diagnosis of schizophre-
nia according to DSM-IV criteria.
The inclusion criteria required that patients were all
treated, or had been treated, by conventional antipsychot-
ics (mainly haloperidol) during at least four weeks at an
appropriate dosage. All the recruited subjects gave
informed consent for their participation in the study,
which was approved by the national ethical committee of
Algeria. As first generation antipsychotics were the first
line treatment for schizophrenia in Algeria during thePage 2 of 7
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(1%) was excluded because of treatment with second gen-
eration antipsychotics. The final sample is therefore made
of 100 patients exactly and their 200 parents.
All informations were obtained from a face-to-face sys-
tematic interview by a trained psychiatrist (DB), enriched
by hospital and ambulatory case notes. Treatment
response was systematically assessed, retrospectively and
at the moment of the clinical interview, using the six point
May and Dencker scale [22]. Levels 1 and 2 might indicate
"remission", with no need for a formal rehabilitation pro-
gram. Levels 3 and 4 signify responsiveness to a learning-
based rehabilitation program. Level 5 suggests the require-
ment of continuous, individually oriented, strategies,
including intensive trials of antipsychotics. Level 6 is cho-
sen for patients needing long-term hospitalization [22].
Scores above 3 were considered as reflecting refractori-
ness, and scores below 4, responsiveness, to allow com-
parison with our previous study [20]. Clinical
information was collected using the D.I.G.S., a semi-struc-
tured interview [23] commonly used in psychiatric genet-
ics for the assessment of substance abuse/dependence and
lifetime clinical characteristics of schizophrenia. Negative
and positive symptoms of schizophrenia were evaluated
using the SANS and SAPS scales [24], while current
extrapyramidal symptoms were assessed with the Simp-
son & Angus scale [25].
Statistics
The TDT and the family-based association test (FBAT)
were applied to assess the association of the -1438A/G
polymorphism of the 5-HT2A gene with schizophrenia
and response to first generation antipsychotic [26]. Deter-
mination of the required sample size was based on both
the frequency of the G allele (42% in our previous sample;
[20]) and an estimated genotype relative risk (gamma) of
1.36 (the one calculated in the meta-analysis of case-con-
trol studies [18]). With such values, 110 trios are needed
[27] in order to detect any significant excess (p < 0.05) of
transmission of one allele. For quantitative and binary
variables, potentially transmitted with the -1438A/G pol-
ymorphism, the PBAT test was used [28].
5-HT2A receptor gene polymorphism
Blood was collected after the interview and genomic DNA
was isolated from leucocytes using standard salting out
procedures [29]. Five independent SNPs (not located on
the same chromosome) were tested to check paternity,
without being able to exclude any.
The -1438A/G polymorphism located in the promoter of
the 5-HT2A receptor gene was determined using a
polymerase chain reaction as previously described [30].
Results and discussion
One hundred complete trios with schizophrenic
probands (81 males and 19 females) participated in the
study. Thirty eight patients were considered as good
responders while 62 were not. The non responsive group
was predominant, probably because of the highly
demanding criteria of the May and Dencker scale, and
exhibited significantly higher scores for positive (p <
0.001), negative (p < 0.001) and extra-pyramidal symp-
toms (p < 0.001) (Table 1).
The genotype distribution of the trios was in accordance
with Hardy-Weinberg equilibrium, as well as that of each
of the two subgroups of patients with good versus poor
response to treatment. No allele of the -1438A/G poly-
morphism was transmitted in excess in the whole sample
of patients with schizophrenia (Mc Nemar χ2 = 1.63, p =
0.20). However, an excess of transmission of the G allele
was observed in the responsive group (Mc Nemar χ2 = 5.
26, p = 0.02) but not in the non-responsive group (Mc
Nemar χ2 = 0.01, p = 0.90) (Table 2, Figure 1), the number
of informative transmissions being limited (23 good
responders versus 65 poor responders).
Major clinical variables did not apparently interfere in the
association between the G allele and the group of patients
responsive to treatment, as we found no association,
according to the PBAT test, between the G allele and dura-
Table 1: Demographic and clinical charateristics of the 100 patients with schizophrenia according to good versus poor response to 
antipsychotics (May and Denker classification).
Clinical variables Poor responders (N = 65) Good responders (N = 38) p
Men (%) 77 87 0.445
Age at interview (mean ± sd)* 32.83 ± 7.89 31.33 ± 7.21 0.368
Age at onset (mean ± sd)* 21.66 ± 5.02 21.03 ± 3.45 0.464
Illness duration (mean ± sd) 11.17 ± 8.16 10.29 ± 6.78 0.554
SAPS scores (mean ± sd) 5.14 ± 3.75 1.35 ± 2.84 < 0.001
SANS scores (mean ± sd) 12.11 ± 4.62 9.02 ± 4.29 < 0.001
Extra-pyramidal scores (mean ± sd) 2.86 ± 3.63 0.92 ± 1.55 < 0.001
* yearsPage 3 of 7
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= 0.41) and extrapyramidal (p = 0.41) symptoms, nor
with the age at onset (p = 0.96). Therefore, it can be con-
cluded that the TDT strategy allowed us to show that the
G allele off the -1438A/G polymorphism was transmitted
in excess among schizophrenic patients responsive to first
generation antipsychotics (haloperidol) in our sample.
Interestingly, an excess in G allele transmission was also
noted in our previous study based on a case-control
approach in schizophrenic patients treated by second gen-
eration antipsychotics [20]. Because this association was
also detected for amisulpride (which has a very low affin-
ity for 5-HT2A receptor) in the latter study, and the risk of
stratification bias was eliminated in the present study, it
can be reasonably inferred that the 5-HT2A gene could be
involved in clinical or other traits tagging specific sub-
groups of patients, with higher chance of improvement by
treatment with various antipsychotics, whatever their
affinity for 5-HT2A receptors. As some first generation
antipsychotics may exert some moderate but meaningful
Percentage of observed (versus expected) transmission of the G allele (and their 95% CI) of the 5-HT2A gene in 100 patients with schizophrenia (with 88 informative ones having at leas  one heterozygous parent), and in two subgroups according to clin-ical r sponse t  f rst generation antipsycho icsFigure 1
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Table 2: Transmission disequilibrium test (TDT) for the G allele of the -1438A/G polymorphism of the 5-HT2A gene in a sample of 100 
trios with schizophrenia according to good versus poor response to antipsychotics (May and Denker classification).
Sample G allele χ2 p
Transmitted Untransmitted
All patients 50 38 1.63 0.20
Good treatment response 17 6 5.26 0.02
Poor treatment response 33 32 0.01 0.90Page 4 of 7
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chotics may not depend on receptor antagonism, but
rather on intracellular mechanisms, alternative explana-
tions can be proposed.
As positive and negative symptoms as well as extra-pyram-
idal symptoms were greater among poorly responsive
patients, these clinical features might have acted as inter-
mediate factors between the 5-HT2A gene polymorphism
and response to treatment. In fact, no link was found
between these factors and the G allele of the -1438A/G
polymorphism of the 5-HT2A gene using specific meas-
ures. However, it has to be emphasized that the detection
of such a link in this sample of trios is less obvious than
in our previous case-control study (although both sam-
ples included roughly the same number of probands[20]:
N = 106; present study: N = 100) which allowed the inclu-
sion of all patients (N = 64 responsive patients). With the
TDT, only patients from at least one heterozygous parent
and who exhibited good response to treatment can be
used (N = 23 potential transmissions). Furthermore, the
required sample size was a bit over the one we had in this
study (i.e. we reached only 91% of the targeted recruit-
ment). Therefore, the chance to detect such a link is
greatly reduced, even when using quantitative trait loci
(QTL) with the PBAT software. Difference of statistical
power was already raised in one positive case-control
study but it was negative in the familial association study
concerning the T102C polymorphism of the 5-HT2A gene
in schizophrenia [31]. Furthermore, the TDT approach is
based on the assumption that both participating parents
are the biological ones, which might be wrong for a signif-
icant part of the fathers. Even if we probably decreased
this risk by testing 5 independent SNPs, more informative
markers (i.e. VNTR) on a larger set of genes (i.e. more than
5) would have been more appropriate to detect exclusion
of parternity.
The -1438A/G polymorphism was found to be associated
with first generation antipsychotic efficacy in our sample.
Efficacy in this sample was relying on May and Dencker
scale, which is based on past treatments. Retrospective
analysis may have different advantages, as allowing the
assessment of longer periods, the comparison of the effi-
cacy of different treatments in a single patient, and being
protected from the problem of follow-up (with the associ-
ated attrition rate). On the other hand, such assessment is
more exposed to different confounding parameters such
as an uncontrolled length of exposition and dosage to dif-
ferent treatments, and a lower validity of assessment.
These limits should be taken into account. Comparison
with available data in the literature cannot really be made
because the largest part of psychopharmacogenetics stud-
ies on antipsychotics in schizophrenia concern second
generation antipsychotics. Furthermore, reported studies
mainly relied on the T102C polymorphism. Nevertheless,
it is interesting to note that the meta-analyses of antipsy-
chotic response by Arranz et al. [17,18], and of schizo-
phrenia per se by Abdolmaleki et al. [8], are in favor of a
significant role of the C allele of the T102C polymor-
phism, which mainly corresponds to the G allele of the -
1438A/G polymorphism, as these two markers are in
nearly complete linkage disequilibrium. The conclusion
would then be that the allele which was associated with
good response to antipsychotics and the risk of schizo-
phrenia was in fact less frequent in our sample of patients
with good response. Three points have to be raised in
front of such discrepant results.
Firstly, in meta-analyses, large inter-studies variability of
the G allele frequency was detected, with a tendency in
favour of an association with the other allele (equivalent
to the A allele of the -1438A/G polymorphism) in samples
of non-Caucasian subjects. However, a large prospective
study in an Asian sample [19] showed that the G allele
was associated with good response, in accordance with
our previous study [20] and the data reported herein. Such
discrepancy in the results can be ascribed to the variability
of the G allele frequency in different ethnic backgrounds,
and tends to favor intra-familial, rather than case-control,
association studies. In any case, because of the rather
modest number of informative transmissions (50 allelic
transmissions among the 200 available for the 100 trios,
and 17 allelic transmissions of the 76 available in the
responsive group), our results should be interpreted with
caution [27], the risk of chance finding being high. Using
more tagging single nucleotide polymorphisms (tag-
SNPs), including the T102C polymorphism, would
improve the statistical power of the analyses (because of
the higher rate of heterozygous parents) and would help
to pinpoint which haplotype might be involved in treat-
ment response for this gene. Furthermore, the probability
that different SNPs from many other genes are involved in
treatment response is high, in accordance with the rela-
tively small attributable risk usually detected in psychop-
harmacogenetic studies.
Secondly, as recalled above, the majority of pharmacoge-
netic studies were performed on second generation antip-
sychotics, and mainly on clozapine, in accordance with
the need to identify patients that can benefit of such effec-
tive but potentially life-threatening treatment. This
implies that mostly severe and resistant patients have
been included in these studies, in contrast with our sam-
ple and that of the Lane et al. [19] study which comprised
both good responders and poor responders to antipsy-
chotics. Similarities in the recruitment of the latter two
samples probably explain why the data of Lane et al. [19]
and ours are convergent.Page 5 of 7
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morphism of the 5-HT2A gene is not yet clear. Many stud-
ies propose that this polymorphism might allow
prediction of resistance to treatment [18], while others
claim that the G allele could be an independent risk factor
for schizophrenia [8]. Our data suggest that the G allele
tags a subgroup of patients with schizophrenia (with
enough power so that meta-analysis is positive in schizo-
phrenia) which may have greater chance of improvement
by different types of antipsychotics.
How could the G allele of the 5-HT2A gene be related to
global treatment refractoriness in schizophrenia? The T
allele of T102C polymorphism was found associated with
a higher expression of 5-HT2A mRNA and protein [32,33].
Because the T allele theoretically corresponds to the A
allele of the -1438A/G polymorphism [34], patients with
the G allele might have lower brain densities of 5-HT2A
receptors. Extensive convergent studies showed that 5-
HT2A receptor blockade is useful in the treatment of psy-
chosis [35]. Whether the G allele-associated 5-HT2A down
expression contributes to make schizophrenic patients
more prone to respond to antipsychotic treatment is an
interesting possibility that deserves further investigations.
The gene coding for the D2 dopamine receptor remains a
core candidate gene for pharmacogenetic studies devoted
to schizophrenia, as all antipsychotics share a variable but
significant affinity for this receptor [4].
Conclusion
Using a TDT approach, the G allele of the -1438A/G poly-
morphism of the gene coding for the 5-HT2A receptor was
found to be transmitted in excess in a subgroup of schizo-
phrenic patients who were good responders to first gener-
ation antipsychotics (mainly haloperidol), the specificity
of this finding (transmission of the vulnerability allele
from parents to the proband, rather than direct associa-
tion) being counterbalanced by the limited number of
informative patients.
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